EBIT: Income before interest and taxes.
Actinium Pharmaceuticals, Inc. (ATNM) had EBIT of $-36.25M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.09M |
|
$-33.89M |
|
-- |
|
$0.09M |
|
$36.34M |
|
$-36.25M |
|
$2.36M |
|
$-33.89M |
|
$-33.89M |
|
$-33.89M |
|
$-33.89M |
|
$-33.89M |
|
$-33.89M |
|
|
EBIT |
$-36.25M |
$-35.43M |
|
31.20M |
|
31.20M |
|
$-1.09 |
|
$-1.09 |
|
| Balance Sheet Financials | |
$49.38M |
|
$0.29M |
|
$2.39M |
|
$51.77M |
|
$7.97M |
|
-- |
|
$35.97M |
|
$43.94M |
|
$7.83M |
|
$7.83M |
|
$7.83M |
|
31.20M |
|
| Cash Flow Statement Financials | |
$-24.58M |
|
$-0.10M |
|
$-0.22M |
|
$73.23M |
|
$48.33M |
|
$-24.89M |
|
$9.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.20 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-40274.45% |
|
-40274.45% |
|
-39362.22% |
|
-37652.22% |
|
-37652.22% |
|
$-24.68M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-432.56% |
|
-432.56% |
|
-65.45% |
|
-432.56% |
|
$0.25 |
|
$-0.79 |
|
$-0.79 |
|